ClinicalTrials.gg
CompletedNCT02517905Updated Dec 10, 2020Results posted

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

A Phase 3 interventional study of Bupivacaine liposome and Placebo in Dental Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-10.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.

Enrollment
27th of 50
166 · median 194
Started
2015
the only one that year
Phase 3
11 of 54
none open now
Registered
35th of 54
by date

Among the 54 studies in Toothache with a site in United States, this one is the 27th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2015, is one of 11 in phase 3, and was the 35th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind, placebo-controlled study in subjects scheduled to undergo elective bilateral third molar extraction under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiographic evidence.

Read the detailed description

Subjects will be screened within 30 days prior to surgery.

Randomized subjects will receive a dental nerve block with lidocaine 2% with epinephrine 1:100,000 before undergoing bilateral third molar extraction under local anesthesia. In addition to the lidocaine nerve block, the Investigator may choose to add topical benzocaine or intraoperative nitrous oxide.

At the end of surgery, and at least 20 minutes after the lidocaine administration, blinded study drug will be infiltrated to provide postsurgical analgesia. Subjects will be required to remain in the research facility for 96 hours after study drug administration.

Postsurgical efficacy, safety, and pharmacokinetic (PK) assessments will be conducted.

All subjects will return for a follow-up visits on Days 7 and 10. A phone call will be made to each subject on Day 30 for an adverse event (AE) assessment and to inquire as to whether the subject made any unscheduled phone calls or office visits related to pain.

03

Conditions studied

  • Dental Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ≥18 years of age at screening.
  2. Scheduled to undergo bilateral third molar extractions (i.e., extraction of all four third molars) under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiological evidence.
  3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.
  4. Female subjects must be either surgically sterile, using a medically acceptable method of , or at least 2 years , and must have a documented negative pregnancy test result during screening and on Day 1 prior to surgery.
  5. Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  1. History of or idiosyncratic reaction to amide-type local anesthetics or opioids.
  2. to lidocaine, epinephrine, bupivacaine, or oxycodone.
  3. History of significant drug allergy (e.g., anaphylaxis or hepatotoxicity).
  4. Positive test result from the urine drug screen at screening or prior to the surgical procedure.
  5. Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  6. History or active psychiatric illness (including major depression, bipolar disorder, or anxiety); Type 1 or Type 2 diabetes; severe renal or hepatic impairment; significant cardiovascular disease (including cardiac rhythm disturbance); migraine headaches, frequent headaches, other pain conditions, or other medical condition that, in the opinion of the Investigator, may increase the risk of surgery or interfere with the evaluation of the study drug.
  7. History of infection requiring intravenous (IV) antibiotics within 45 days or oral (PO) antibiotics within 30 days prior to study drug administration for reasons other than dental prophylaxis. Subjects must be afebrile, without signs or symptoms indicative of active infection.
  8. Use of any of the following medications within the times specified before surgery: long-acting opioid medication, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin (except for low-dose aspirin used for cardioprotection), or acetaminophen within 3 days, or any opioid medication within 24 hours.
  9. Initiation of treatment with any of the following medications within 1 month of EXPAREL infiltration or if the medication(s) are being given to control pain: selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is taking one of these medications for a reason other than pain control, he or she must be on a stable dose for at least 1 month prior to EXPAREL administration.
  10. Current use of systemic glucocorticosteroids within 1 month of enrollment in this study.
  11. Use of any concurrent therapy that could interfere with the evaluation of efficacy or safety, such as any drugs which in the Investigator's opinion may exert significant analgesic properties or act synergistically with the product.
  12. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    EXPAREL 133 mg

    10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration

    Drug: Bupivacaine liposome

  • Placebo comparator
    Placebo

    10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration

    Drug: Placebo

Interventions

  • Local administration

    Also known as: EXPAREL

  • DrugPlacebo

    Local administration

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours

    AUC of NRS pain intensity scores through 48 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)

    Time frame: 0-48 hours

Secondary outcomes

  1. Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours

    AUC of NRS pain intensity scores through 24 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain) 0-24 hours

    Time frame: 0-24 hours

  2. Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours

    AUC of NRS pain intensity scores through 72 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)

    Time frame: 0-72 hours

  3. Percentage of Opioid-free Subjects Through 24 Hours.

    Percentage of opioid-free subjects through 24 hours.

    Time frame: 0-24 hours

  4. Percentage of Opioid-free Subjects Through 48 Hours.

    Percentage of opioid-free subjects through 48 hours.

    Time frame: 0-48 hours

  5. Percentage of Opioid-free Subjects Through 72 Hours.

    Percentage of opioid-free subjects through 72 hours.

    Time frame: 0-72 hours

07

Results

Posted Dec 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneEXPAREL 133 mgPlacebo
Started10759
Completed9757
Not completed102
Withdrew: Lost to follow-up40
Withdrew: Withdrawal by subject40
Withdrew: Screen failure22

Outcome measures

PrimaryArea Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours

AUC of NRS pain intensity scores through 48 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)

Time frame:
0-48 hours
Reported as:
Least squares mean · units on NRS scale*hr
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours
units on NRS scale*hrEXPAREL 133 mgPlacebo
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours178.9 ± 10.30181.6 ± 13.63
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = 0.8661 · Lsmd: -2.7 · 95% CI -33.5 to 28.2
SecondaryArea Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours

AUC of NRS pain intensity scores through 24 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain) 0-24 hours

Time frame:
0-24 hours
Reported as:
Least squares mean · units on NRS scale*hr
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours
units on NRS scale*hrEXPAREL 133 mgPlacebo
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 24 Hours102.4 ± 4.73106.4 ± 6.26
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = 0.5780 · Lsmd: -4.0 · 95% CI -18.2 to 10.2
SecondaryArea Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours

AUC of NRS pain intensity scores through 72 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)

Time frame:
0-72 hours
Reported as:
Geometric least squares mean · units on NRS scale*hr
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours
units on NRS scale*hrEXPAREL 133 mgPlacebo
Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 72 Hours241.5 ± 15.40235.6 ± 20.38
Statistical analysis
  • EXPAREL 133 mg vs Placebo · ANOVA · p = 0.8010 · Lsmd: 5.9 · 95% CI -40.2 to 52.1
SecondaryPercentage of Opioid-free Subjects Through 24 Hours.

Percentage of opioid-free subjects through 24 hours.

Time frame:
0-24 hours
Reported as:
Count of participants · Participants
Percentage of Opioid-free Subjects Through 24 Hours.
ParticipantsEXPAREL 133 mgPlacebo
Percentage of Opioid-free Subjects Through 24 Hours.1912
SecondaryPercentage of Opioid-free Subjects Through 48 Hours.

Percentage of opioid-free subjects through 48 hours.

Time frame:
0-48 hours
Reported as:
Count of participants · Participants
Percentage of Opioid-free Subjects Through 48 Hours.
ParticipantsEXPAREL 133 mgPlacebo
Percentage of Opioid-free Subjects Through 48 Hours.1912
SecondaryPercentage of Opioid-free Subjects Through 72 Hours.

Percentage of opioid-free subjects through 72 hours.

Time frame:
0-72 hours
Reported as:
Count of participants · Participants
Percentage of Opioid-free Subjects Through 72 Hours.
ParticipantsEXPAREL 133 mgPlacebo
Percentage of Opioid-free Subjects Through 72 Hours.1812

Adverse events

Collected over From screening to postsurgical day 29. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXPAREL 133 mg0/105 (0%)0/105 (0%)105/105 (100%)
Placebo0/57 (0%)0/57 (0%)57/57 (100%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEXPAREL 133 mgPlacebo
Hypoesthesia oralNervous system disorders104/10557/57
DysgeusiaNervous system disorders80/10532/57
NauseaGastrointestinal disorders32/10516/57
Muscle contractions involuntaryNervous system disorders16/10512/57
VomitingGastrointestinal disorders18/1059/57
HeadacheNervous system disorders6/1059/57
DizzinessNervous system disorders11/1058/57
Post procedural edemaInjury, poisoning and procedural complications10/1057/57
Muscle twitchingMusculoskeletal and connective tissue disorders8/1054/57
Upper respiratory tract infectionInfections and infestations4/1052/57

Baseline characteristics

Safety population included all participants who received study drug, with analysis by actual treatment received.

Age, Continuous
Age, Continuous(years)EXPAREL 133 mgPlaceboTotal
Mean20.9 ± 3.8120.9 ± 4.7620.9 ± 4.15
Sex: Female, Male
Sex: Female, Male(Participants)EXPAREL 133 mgPlaceboTotal
Female533386
Male522476
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EXPAREL 133 mgPlaceboTotal
Hispanic or Latino16723
Not Hispanic or Latino8950139
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EXPAREL 133 mgPlaceboTotal
American Indian or Alaska Native101
Asian022
Native Hawaiian or Other Pacific Islander011
Black or African American9110
White9453147
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)EXPAREL 133 mgPlaceboTotal
United States10557162
Body Mass Index
Body Mass Index(kg/m2)EXPAREL 133 mgPlaceboTotal
Mean25.8 ± 6.8724.5 ± 4.7225.3 ± 6.21
Impaction Scores
Impaction Scores(Participants)EXPAREL 133 mgPlaceboTotal
4 fully bony impacted teeth231942
3 fully bony impacted teeth, 1 partially impacted14721
3 fully bony impacted teeth134
2 fully bony impacted teeth, 2 partially impacted10717
2 fully bony impacted teeth, 1 partially impacted9211
2 fully bony impacted teeth369
1 fully bony impacted tooth, 3 partially impacted415
1 fully bony impacted tooth, 2 partially impacted7310
1 fully bony impacted tooth, 1 partially impacted8513
1 fully bony impacted tooth224
4 partially impacted teeth303
3 partially impacted teeth404
2 partially impacted teeth16117
1 partially impacted tooth112
No impactions000
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2020, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2015
First posted
Aug 7, 2015
Start
Aug 2015
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Dec 10, 2020
Last update
Dec 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02517905
Collaborators
Lotus Clinical Research, LLC
Responsible party
Sponsor
First posted
Aug 7, 2015
Start date
Aug 2015
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Dec 10, 2020
Last update
Dec 10, 2020

Study contacts

Jim Jones, MD, PharmD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion